Follow-The-Filings

Security

ALLO

Allogene Therapeutics Inc. · COM

Equity holders as of 2026 Q1 (each manager’s latest book)

11 owners 1 new max 0.0% (Marshall Wace - Marshall ...)

grid → activity →
owners 11
max % 0.0%
tracked value $72M
qoq N 1 A 6 R 3

holders

sorted by % of portfolio · long equity only

manager % port activity shares value history
Marshall Wace - Marshall Wace, LLP 2026 Q1 0.0% Add +0.01 pp 3,447,984 $8M hist
Renaissance Technologies LLC 2026 Q1 0.0% Reduce 0.00 pp 2,139,328 $5M hist
Two Sigma Investments, LP 2025 Q4 stale 0.0% Exit -0.01 pp 3,423,441 $5M hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% Reduce 0.00 pp 6,793,620 $17M hist
Vanguard Group Inc. 2025 Q4 stale 0.0% Add 0.00 pp 9,251,609 $13M hist
Israel Englander - Millennium Management LLC 2026 Q1 0.0% Add 0.00 pp 3,322,053 $8M hist
D. E. Shaw & Co., Inc. 2026 Q1 0.0% Add 0.00 pp 2,763,776 $7M hist
Cliff Asness - Aqr Capital Management LLC 2026 Q1 0.0% Add 0.00 pp 2,484,780 $6M hist
Dmitry Balyasny - Balyasny Asset Management L.P. 2026 Q1 0.0% New 0.0% 1,182,816 $3M hist
Steve Cohen - Point72 Asset Management, L.P. 2026 Q1 0.0% Add 0.00 pp 221,335 $540 hist
Murray Stahl - Horizon Kinetics Asset Management LLC 2026 Q1 0.0% Reduce 0.00 pp 17,582 $43 hist

11 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $30,000 $22,000 $0.00
Gross profit — — —
Gross margin — — —
Net income -$99.97M -$257.59M -$190.89M
Net margin * -333226.7% -1170863.6% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $481.46M $303.39M $257.75M
Total non-current assets * $268.66M $245.32M $158.16M
Total assets $750.13M $548.71M $415.9M
Total current liabilities $59.4M $35.52M $32.51M
Total non-current liabilities * $98.72M $91.01M $90.85M
Total equity $592.01M $422.18M $292.54M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$66.64M -$200.3M -$149.25M
Cash from investing $163.29M $75.69M $95.56M
Cash from financing $95.7M $116.68M $30.16M
Net change in cash $21.25M -$7.94M -$23.53M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders